A research team from Tel Aviv University, led by Prof. Shamgar Ben-Eliyahu and Prof. Oded Zmora, investigated cancer mortality, which in most cases results from the development of metastatic disease in different organs of the body.

They found that inflammatory and stress-related processes that promote metastasis can be significantly attenuated through a combination of two well-known and safe medications.

In a pilot clinical study that followed 34 patients over five years, the rate of metastasis was 50% in the control group that did not receive the treatment, compared to only 12.5% in the group that received it. In addition, according to molecular markers, tumor tissue in treated patients showed a less metastatic profile.

We are now conducting a necessary large-scale study, aimed at establishing this treatment as a standard protocol for the prevention of metastasis. To achieve this, we must recruit 340 patients.

The cost of recruiting each patient is approximately ₪10,000 paid to the treating hospital, about ₪1,500 for medication preparation paid to Super-Pharm, and approximately ₪3,000 for molecular analyses of tumor tissue - a total of ₪14,500 per patient.($4,530 per patient)

As a non-profit study with no financial support from pharmaceutical companies, every donation enables us to recruit an additional patient, with the hope of saving their life, and, in the future, many others.

*Donations are tax-deductible under Section 46 of the Israeli Income Tax Ordinance.